公开(公告)号：US20240239752A1

公开(公告)日：2024-07-18

申请号：US18286615

申请日：2022-04-14

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Zhao Dang ,  Krishnan Raman

IPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

摘要： Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.

公开(公告)号：US12020872B2

公开(公告)日：2024-06-25

申请号：US18156925

申请日：2023-01-19

申请人： AMBIENT PHOTONICS, INC.

发明人： John C. Warner

IPC分类号： H01G9/20 ,  C07D307/79 ,  C07D307/81 ,  C09B23/10 ,  C09B23/14 ,  C09B57/00 ,  H10K85/60 ,  H10K30/15 ,  H10K102/10

CPC分类号： H01G9/2059 ,  C07D307/79 ,  C07D307/81 ,  C09B23/105 ,  C09B23/148 ,  C09B57/008 ,  H10K85/636 ,  H10K30/151 ,  H10K85/6574 ,  H10K2102/102 ,  Y02E10/542 ,  Y02E10/549 ,  Y02P70/50

摘要： The present application discloses stilbene derivative compounds and phenylbenzofuran compositions, useful in the manufacture of dye-sensitized solar cells and other similar technology.

公开(公告)号：US20230382883A1

公开(公告)日：2023-11-30

申请号：US18362073

申请日：2023-07-31

申请人： VANDA PHARMACEUTICALS INC.

发明人： Deepak Phadke ,  Natalie M. Platt ,  Ravi K. Pandrapragada

IPC分类号： C07D307/81 ,  C07D307/79

CPC分类号： C07D307/81 ,  C07D307/79

摘要： A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.

公开(公告)号：US11787775B2

公开(公告)日：2023-10-17

申请号：US17383422

申请日：2021-07-22

申请人： Genentech, Inc.

发明人： Jason R. Zbieg ,  Paul Powell Beroza

IPC分类号： C07D307/81 ,  C07D213/74 ,  C07D277/64 ,  C07D405/10 ,  C07D409/10 ,  C07D417/10 ,  C07D491/048 ,  C07F5/02

CPC分类号： C07D307/81 ,  C07D213/74 ,  C07D277/64 ,  C07D405/10 ,  C07D409/10 ,  C07D417/10 ,  C07D491/048 ,  C07F5/025

摘要： The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

公开(公告)号：US11767305B2

公开(公告)日：2023-09-26

申请号：US18077966

申请日：2022-12-08

申请人： Tactogen Inc

发明人： Matthew Baggott

IPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

CPC分类号： C07D307/81 ,  A61P25/18 ,  A61P25/24

摘要： Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

公开(公告)号：US20230203062A1

公开(公告)日：2023-06-29

申请号：US18057742

申请日：2022-11-21

申请人： Genentech, Inc.

发明人： Jason Robert ZBIEG ,  Paul Powell BEROZA ,  Vishal Anil VERMA ,  Bing-Yan ZHU ,  Ramsay BEVERIDGE ,  Liang ZHAO ,  Melissa LEBLANC ,  Lisa Marie BARTON ,  Bryan Ka Ip CHAN ,  Samir BOUAYAD-GERVAIS ,  Anwesha DEY ,  Marie Anne EVANGELISTA ,  Russell Tyler SMITH

IPC分类号： C07D513/04 ,  C07D307/81 ,  C07D413/04 ,  C07D491/052 ,  C07D471/04 ,  C07D239/74 ,  C07D491/048 ,  C07D498/04 ,  C07D215/12 ,  C07D405/08 ,  C07D403/06 ,  C07D235/14 ,  C07D487/04 ,  C07D241/42 ,  C07D263/56

CPC分类号： C07D513/04 ,  C07D307/81 ,  C07D413/04 ,  C07D491/052 ,  C07D471/04 ,  C07D239/74 ,  C07D491/048 ,  C07D498/04 ,  C07D215/12 ,  C07D405/08 ,  C07D403/06 ,  C07D235/14 ,  C07D487/04 ,  C07D241/42 ,  C07D263/56

摘要： This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

公开(公告)号：US20230183239A1

公开(公告)日：2023-06-15

申请号：US17702597

申请日：2022-03-23

申请人： AbbVie Inc.

发明人： William Michael GALLATIN ,  Joshua ODINGO ,  Gregory N. DIETSCH ,  Vincent FLORIO ,  Chandregowda VENKATESHAPPA ,  Athisayamani Jeyaraj DURAISWAMY

IPC分类号： C07D471/10 ,  C07D211/28 ,  C07D215/233 ,  C07D215/44 ,  C07D239/88 ,  C07D239/94 ,  C07D241/42 ,  C07D307/81 ,  C07D311/22 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00 ,  C07F5/02

CPC分类号： C07D471/10 ,  C07D211/28 ,  C07D215/44 ,  C07D215/233 ,  C07D239/88 ,  C07D239/94 ,  C07D241/42 ,  C07D307/81 ,  C07D311/22 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00 ,  C07F5/025

摘要： Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

公开(公告)号：US20230150964A1

公开(公告)日：2023-05-18

申请号：US18149590

申请日：2023-01-03

申请人： VANDA PHARMACEUTICALS INC.

发明人： Deepak Phadke ,  Natalie M. Platt ,  Ravi K. Pandrapragada

IPC分类号： C07D307/81 ,  C07D307/79

CPC分类号： C07D307/81 ,  C07D307/79

摘要： A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.

公开(公告)号：US20230143250A1

公开(公告)日：2023-05-11

申请号：US17891436

申请日：2022-08-19

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  Jun Ma ,  Brett Granger ,  Jiang Long ,  Bin Wang ,  Sourav Ghorai ,  Jing He ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Yat Sun Or

IPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

CPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

摘要： The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US10047066B2

公开(公告)日：2018-08-14

申请号：US12744860

申请日：2008-12-01

申请人： Mario Mautino ,  Firoz Jaipuri ,  Agnieszka Marcinowicz-Flick ,  Tanay Kesharwani ,  Jesse Waldo

发明人： Mario Mautino ,  Firoz Jaipuri ,  Agnieszka Marcinowicz-Flick ,  Tanay Kesharwani ,  Jesse Waldo

IPC分类号： A61K31/5375 ,  A61K31/135 ,  A61K31/404 ,  A61K31/381 ,  A61K31/505 ,  C07D209/14 ,  C07D405/12 ,  C07D333/56 ,  A61K31/138 ,  A61K31/506 ,  C07C259/06 ,  C07C311/48 ,  C07C327/44 ,  C07C327/48 ,  C07C333/20 ,  C07D209/18 ,  C07D213/40 ,  C07D215/26 ,  C07D253/07 ,  C07D261/20 ,  C07D263/22 ,  C07D277/36 ,  C07D279/06 ,  C07D307/81 ,  C07D333/58 ,  C07D333/60 ,  C07D335/06 ,  C07D401/06 ,  C07D409/12 ,  C07D417/06 ,  C07D417/12 ,  C07D277/64 ,  C07D307/80 ,  A61P37/00 ,  A61K31/4045 ,  C07D403/12 ,  C07D401/12 ,  A61K31/4709 ,  C07D413/12 ,  A61K31/423 ,  C07C333/04 ,  A61K31/27 ,  C07D213/53 ,  A61K31/4406 ,  A61K31/4402 ,  A61K31/36 ,  A61K31/47 ,  A61K31/357 ,  A61K31/428

CPC分类号： C07D333/56 ,  A61K31/138 ,  A61K31/506 ,  C07C259/06 ,  C07C311/48 ,  C07C327/44 ,  C07C327/48 ,  C07C333/20 ,  C07D209/14 ,  C07D209/18 ,  C07D213/40 ,  C07D215/26 ,  C07D253/07 ,  C07D261/20 ,  C07D263/22 ,  C07D277/36 ,  C07D277/64 ,  C07D279/06 ,  C07D307/80 ,  C07D307/81 ,  C07D333/58 ,  C07D333/60 ,  C07D335/06 ,  C07D401/06 ,  C07D405/12 ,  C07D409/12 ,  C07D417/06 ,  C07D417/12 ,  Y02A50/409 ,  Y02A50/465

摘要： Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.